It is concluded that increased levels of plasma TIMP-1, CEA, CA19-9, and serum YKL-40 at large bowel endoscopy without findings may be associated with an increased risk of developing a subsequent malignant disease.īackground: Blood-based, cancer-associated biomarkers may detect subjects at risk of having neoplastic diseases. The cumulative risk of developing malignant disease within the first 5 years after endoscopy was group 0, 3.3% group 1, 5.8% group 2, 7.8%. A multivariate analysis showed that increased biomarker levels were associated with subsequent development of a malignant disease (P = 0.002). Univariatly, increase of all four biomarkers was significantly associated with subsequent development of a malignant disease. A total of 43 subjects developed a primary malignant disease in the observation period. The levels were separated into three groups: 0, none of the biomarkers increased 1, one biomarker increased 2, two or more biomarkers increased. The upper 90% limits of the reference levels of every single protein were used to differentiate between normal and increased levels. Plasma levels of TIMP-1, CEA, CA19-9, and YKL-40 were determined in samples collected just before endoscopy and compared with subsequent development of a malignant disease within a period of 7-8 years. In a major study of 4,990 subjects undergoing large bowel endoscopy, 691 were without pathology and comorbidity. The present study focused on a possible association between increased biomarker levels in such subjects and subsequent development of malignant diseases.
Soluble cancer-related protein biomarker levels may be increased in subjects without findings at large bowel endoscopy performed due to symptoms associated with colorectal cancer.
0 kommentar(er)
